US Biopharmaceuticals: The Biotech Brief: Week of June 19, 2026

Research evidence excerpt

US Biopharmaceuticals: The Biotech Brief: Week of June 19, 2026

Upcoming Catalysts:

Exhibit 1: Upcoming catalysts in our coverage universe

A look ahead at key data, decisions, and milestones. See our catalyst tracker for more.

Ticker Date Catalyst

BIIB 2Q Phase 2 readout of oral BTK inhibitor, BIIB091, in MS

KROS 2Q Initiation of phase 2 basket trial of rinvatercept in DMD

SNDX 7/14/2026 R&D Day highlighting late stage revumenib and axatilimab programs

BIIB 7/12-15/2026 Data presentation of BIIB080 at AAIC

Phase 2 SURF302 NMIBC readout (initial thoughts from our Vegas dinner; our SURF-

TYRA 8/2026

302 preview)

Leqembi IQLIK subcutaneous initiation PDUFA (see our takes on the Leqembi PDUFA

BIIB 8/24/2026

extension)

Source: BofA Global Research

BofA GLOBAL RESEARCH

Upcoming/ Ongoing Conferences:

• European Society for Medical Oncology Gastrointestinal Cancers Congress

(ESMO GI): July 1-4; Munich

• Cell & Gene Therapy Summit (CGT): July 6-8; Boston

• International Society for Stem Cell Research Annual Meeting (ISSCR): July 8-11;

Montreal

• International Society on Thrombosis and Hemostasis Congress (ISTH): July 11-

15; Paris

• Alzheimer’s Association International Conference (AAIC): July 12-15; London

• American Head & Neck Society International Meeting (AHNS): July 18-22;

Boston

Recent Research:

• Will large language models have positive or negative impacts on long-term

cognitive health and the risk of dementia? (JAMA Internal Medicine. 2026 Jun).

• Could a simple blood test predict—and ultimately prevent—lung cancer?

Emerging plasma biomarkers may detect tumor-promoting signals well before

disease is present, pointing to a shift toward earlier, molecularly guided cancer

interception, pending validation and real-world scalability (Cell. 2026 Jun).